Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (3944)	5/31/2001 5:03:29 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) of 52153

KOSP - Hi Peter, The last time I looked at the Niaspan scripts they were actually dropping slightly - something like 20bp. More importantly over recent months they were rather flat. Do you think that the combo of Niaspan with an old line statin will create a market for the drug? It seems to me that the BIG win would come if the market leading statins decided to offer a combo with their drugs on a royalty basis. But wouldn't that require separate Phase III studies. Yet, nothing stands in the way of cardiologists prescribing Niaspan with the leading statins right now. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next